Ï㽶ÊÓƵ

Skip to main content

New Board Appointments for Two Moran Researchers

Wirostko

New Board Appointments for Two Moran Researchers

Clinical Adjunct Associate Professor, Ophthalmology and Visual Sciences, has joined the Scientific Advisory Board (SAB) of The Glaucoma Foundation (TGF). Dr. Wirostko’s specialties are glaucoma and drug and device development.

As noted by the TGF, "Only scientists with the most outstanding credentials and the highest reputation for commitment to glaucoma are ever considered for service. Dr. Wirostko is such an individual. We know that she is honored to join the SAB and we are equally delighted to have her on our team."

The mission of TGF is to fund groundbreaking research and to educate the public about the disease and the importance of early detection to prevent blindness. As a member of the SAB, Dr. Wirostko joins a group of researchers and investigators with extraordinary scientific pedigrees. Members of this body are key participants at TGF’s Annual Scientific Think Tank, bringing together some of the world’s top scientists and clinicians. These gatherings have significantly impacted setting the course to find new treatments and cures for glaucoma.

DeAngelisMargaret DeAngelis, PhD, Associate Professor of Ophthalmology and Visual Science has accepted a position on the editorial board of the Journal of Biophysical Chemistry (JBPC). She has also recently joined the Admissions Committee, School of Medicine, Ï㽶ÊÓƵ of Utah and the Executive Board, Woman’s Eye Health.

Dr. DeAngelis has focused her career on vision research since 1999 when she received a post-doctoral fellowship training grant on macular degeneration as part of the Molecular Basis of Eye Disease program at Harvard Medical School. She has recruited and characterized ethnically diverse populations (including the underserved) throughout the world in an effort to understand the origin and significance of genetic variation and environmental factors associated with AMD as well as other blinding diseases such as diabetic retinopathy and hypertensive retinopathy.